Status:
WITHDRAWN
Absolute Bioavailability Study With Bexagliflozin
Lead Sponsor:
Theracos
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the absolute bioavailability of bexagliflozin following a single oral dose co-administered with an intravenous dose.
Eligibility Criteria
Inclusion
- body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2
- no nicotine and tobacco consumption in the past 3 months
- willing and able to be confined to the clinical research facility as required by the protocol
Exclusion
- clinically significant history of allergy to drugs or latex
- history of alcohol or drug dependence in the past 12 months.
- donation of a significant amount of blood in the past 2 months
- willing to use an adequate form of birth control during the study and for 90 days after discharge from clinic
- exposure to investigational drug in the past 30 days or 7 half-lives of the investigational drug, whichever is longer
Key Trial Info
Start Date :
August 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 16 2018
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03417076
Start Date
August 1 2018
End Date
September 16 2018
Last Update
September 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Site
Madison, Wisconsin, United States, 53704